Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Company Info
Headquarters
Number of Employees
Revenue (in millions)
Contact Info
Visit Website
Tagline
Overview
Company Services
Site Information
Contributors
Contributions
3D Printing
Exploring New Possibilities with 3D Printing of Pharmaceuticals
PAO-02-24-CL-11
Roundtable
What do you see as the most significant regulatory decision or guidance on the horizon for 2024 (or beyond)?
PAO-12-23-RT-02
Viscosity Reduction
Viscosity Reduction with An Excipient Platform and Feasibility Testing Service
PAO-08-23-CL-03
Alternative Excipient
Preparing Today for a Potential Ban on Titanium Dioxide in Pharmaceutical Drug Products
PAO-08-23-CL-01
Roundtable: Artificial Intelligence
In what areas of pharma/biopharma are you most excited to see increased adoption of artificial intelligence (AI) and machine learning?
PAO-07-23-RT-01
API
Enhanced Solubility through API Processing: Salt and Cocrystal Formation
PAO-05-23-CL-04
International Markets
In what international markets do you anticipate significant developments in the near future?
PAO-01-23-RT-02
Disruptive Technology
What do you view as the most disruptive or transformational technology or development on the horizon?
PAO-01-23-RT-01
3D Printing
Advancing Extrusion-Based 3D Printing for Drug Production
PAO-11-022-CL-14
Sweeteners
High-Intensity Sweeteners for Taste Optimization
PAO-11-022-CL-12
Sustainability
What is your plan to build a more sustainable business practice in the coming years?
PAO-10-022--RT-01
Real-Time Monitoring
Raman Spectroscopy as a PAT Tool Advancing Biopharma Manufacturing
PAO-09-022-CL-08
Manufacturing Investment
MilliporeSigma Announces Investment of More Than € 130 Million to Strengthen Manufacturing Capabilities in Molsheim, France
PR-M09-22-02
Lipid Excipients
Regulatory Considerations for Lipid Excipients
PAO-07-022-CL-04
Excipient Quality Assurance
Assuring Excipient Quality for Parenteral Products
Biomanufacturing
Optimizing Fed-Batch Processes with Chemically Defined Media and Feeds
PAO-07-022-CL-02
Unmet Needs
In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?
PAO-06-022--RT-01
Industry Challenges
What do you consider the biggest challenge that the pharma/biopharma industry currently faces?
O-06-022--RT-01
Advanced Excipients
How the Developability Classification System and Advanced Excipients Enable the Formulation of Poorly Soluble APIs
PAO-04-022-CL-07
Bioprocessing
Better Bioprocessing Efficiency Through Centralized Orchestration
PAO-03-022-CL-23
Excipients
Enabling Stable, High-Viscosity Injectable Drug Products with New Excipient Combinations
PAO-01-22-CL-02
Leadership
Q: What’s the key to being a leader in the industry?
PAO-03-022-RT-02
Milestones
Q: What important company milestone do you anticipate reaching in 2022?
PAO-03-022-RT-01
Facility Acquisition
MilliporeSigma Announces Closing of Exelead Acquisition and Plans to Invest More Than € 500 Million in Technology Scale-Up
PR-M02-22-20
Business Development
MilliporeSigma Announces Organizational Transformation to Strengthen CDMO Offering and Accelerate Future Growth
PR-M02-22-03
Granulation
Improving the Handling and Safety of Pharmaceutical Raw Materials Through Dry Granulation
Personalized and Precision Medicine
Q: What do you see as the key innovations or technologies that will make personalized/precision medicine a reality?
PAO-12-21-RT-01
Therapeutic Progress
Q: For what therapeutic area do you think we will see the greatest progress in the coming years?
PAO-12-21-RT-02
Cell and Gene Therapy
2021 Roundup: The Year of Cell and Gene Therapy
Biomanufacturing
Boosting Cell Densities and Productivity with Tailored Media in Seed Train
PAO-11-21-CL-17
Formulation
Accelerating Biologics Development with High-Quality Protein Stabilization Excipients
PAO-11-21-CL-12
Gene Therapy
Pandemic Playbook for Gene Therapy Manufacturing
PAO-09-21-CL-14
Tablet Coating
An Easy-to-Use Tablet Coating Polymer to Increase Coating Process Efficiency and Flexibility
PAO-09-21-CL-06
3D Printing
Transferring 3D Printing into Pharma: The Journey Has Begun
PAO-07-21-CL-04
eData Exchange
Innovating to Realize the Benefits of Data Sharing
PAO-06-21-CL-13
Antibody-Drug Conjugates
Accelerating ADC Development with Advanced Payload Intermediates
PAO-06-21-CL-11
Biocompatibility
Championing In Vitro Biocompatibility/Biological Reactivity Testing for Plastics Used in Pharma Manufacturing
PAO-06-21-CL-09
mRNA Therapies
Realizing the Promise of RNA Therapies with Lipid Nanoparticle Delivery
PAO-06-21-CL-08
Viral Inactivation
Continuous Inline Viral Inactivation for Next-Generation Bioprocessing
PAO-05-21-CL-06
Grant Program Winner
MilliporeSigma Announces VectorY as Winner of its Advance Biotech Grant
PR-M05-21-015
Cell and Gene Therapy
Reducing the Risk During Cell and Gene Therapy Development and Manufacturing
PAO-03-21-CL-9
Gene Therapy
Avoiding Costly And Time-Consuming Mistakes In Gene Therapy Process Development
PAO-03-21-CL-08
Biopharmaceutical Manufacturing
Bridging the Biopharmaceutical Manufacturing Digital Divide
PAO-03-21-CL-04
Process Intensification
Factory of the Future Will Be a Convergence of Digital and Bioprocessing Technologies
PAO-02-21-CL-03
Nitrosamine
Supporting Drug Manufacturers with Emprove® Nitrosamine Declarations
PAO-02021-CL-05
Gene Therapy
Beyond 2020: Looking into the Crystal Ball for Gene Therapy
PAO-01-21-CL-03
Hot Melt Extrusion
Solving Solubility Challenges with a Polyvinyl Alcohol Excipient and Hot Melt Extrusion
PAP-Q4-20-CL-016
Extractables & Leachables
Aiding Material Qualification and Risk Assessment for Single-Use Biomanufacturing
PAP-Q4-20-CL-015
Antibody–Drug Conjugates
Preparing for the ADC Explosion with End-to-End Support
PAP-Q4-20-CL-014
Gene Therapy
Anticipating the Next Decade of Gene Therapy
PAO-11-20-CL-02
Orally Disintegrating Tablets
Qualifying ODT Excipient Systems Beyond Disintegration Performance
PAO-10-20-CL-03
Wet Granulation
The Application of Mannitol In Wet Granulation
PAO-10-20-CL-01
Lipid Excipients
Successful Drug Development with Synthetic Lipids: Critical Aspects and Strategies
PAP-Q3-20-CL-024
Clinical Trials
Celyad Oncology Announces Clinical Trial Collaboration to Evaluate CYAD-101 with KEYTRUDA
PR-M09-20-32
Expansion
MilliporeSigma Announces $65 Million Antibody-Drug Conjugate Manufacturing Expansion
PR-M09-20-NI-14
Capacity Expansion
MilliporeSigma Invests $20 Million in New Switzerland Laboratory
PR-M07-20-NI-022
Depth Filtration
Robust Harvest Clarification for Adeno-Associated Viral Vectors via Depth Filtration
PAP-Q2-20-CL-030
Capacity Expansion
MilliporeSigma Boosts Commercial Viral Vector and Gene Therapy Manufacturing Capacity with $110 Million Facility
PR-M04-20-NI-032
Purification
High-Productivity Membrane Chromatography to Enable Next-Generation Purification of Monoclonal Antibodies
PAP-Q4-19-CL-023
Biopharma
Bioprocess of the Future: What’s In it for Biomanufacturers?
PAP-Q2-2019-CL-026
M Lab
MilliporeSigma Opens First M Lab™ Collaboration Center in Europe
PR-M03-19-NI-060
CRISPR
MilliporeSigma Awarded Canadian CRISPR Nickase Patent for Foundational Genome-Editing Technology
PR-M03-19-NI-009
Awards
MilliporeSigma Wins Two R&D 100 Awards for Innovation in 2018
PR-M11-18-NI-101
CRISPR
MilliporeSigma Awarded Australian CRISPR Nickase Patent for Foundational Genome-Editing Technology
PR-M09-18-NI-046
CRISPR
MilliporeSigma Receives Two More Patents for CRISPR Technology
PR-M02-18-NI-86
OEM
BioLife Solutions Executes OEM Agreement with MilliporeSigma
PR-M02-18-NI-57
Innovation
MilliporeSigma Expands Celonic's Upstream Capabilities with Mobius® Single-use Bioreactors
PR-M09-17-NI-004
CRISPR
MilliporeSigma Increases the Efficiency of Gene Editing
PAO-M05-17-NI-030
Innovation
Millipore Sigma Sponsoring LabCentral
PAO-M05-17-NI-002